



PRESS RELEASE

16 April 2026

CEPI awards seed funding to Analysis Zero to advance real-time RNA vaccine quality testing using NMR technology

- *CEPI funds Analysis Zero, a Recipharm company, to explore real-time RNA vaccine testing using NMR*
- *Aims to replace multi-day testing with real-time CQA monitoring*
- *Potential to speed batch release, cut costs and improve global access*

CEPI and Analysis Zero, a Recipharm company, have announced a new seed collaboration to advance the use of Nuclear Magnetic Resonance (NMR) as a real-time Process Analytical Technology (PAT) for RNA vaccine manufacturing.

The objective of the project, funded by CEPI, is to address one of the key bottlenecks in RNA vaccine production: the time required to measure and assure critical quality attributes (CQAs). Current approaches often rely on multiple sequential assays, with testing timelines extending over several days and adding complexity to time-sensitive manufacturing processes.

Aaron Cowley, Chief Scientific Officer at Analysis Zero, said: "Our work with CEPI will evaluate how NMR technology can be integrated directly into the manufacturing workflow to enable real-time, simultaneous monitoring of multiple CQAs. By shifting from traditional off-line testing to in-line analytical measurement, our new method has the potential to significantly accelerate quality assessment and batch release timelines, enabling faster manufacturing process."

Analysis Zero brings deep expertise in advanced analytical technologies and process integration, while Recipharm contributes its extensive experience in biologics development and manufacturing. Together, the teams will explore how this innovative PAT approach can simplify quality control while maintaining the highest standards of product integrity.

By reducing reliance on specialized analytical infrastructure and enabling faster decision-making during production, the NMR-based solution offers the potential to lower manufacturing costs and improve scalability. Importantly, this innovation may also support more accessible vaccine manufacturing in regions with limited analytical capacity, contributing to greater global health equity.

Looking ahead, the collaboration represents an important step toward transforming how quality is measured in RNA vaccine production. CEPI and Analysis Zero share a commitment to advancing technologies that enable faster, more efficient, and more responsive manufacturing systems, which are critical capabilities in preparing for, and responding to, future epidemic and pandemic threats.

Ends)

For more information

About Analysis Zero

Analysis Zero's mission is to democratize access to high quality, affordable biologics by fundamentally re-designing how quality control, analytics and process intelligence are delivered. By combining mobile, modular hardware (PAT-Skid) with integrated software, real time analytics, and digital twin models (iPATintelligence and Simulator), Analysis Zero enables faster development,



lower cost of goods, regulatory aligned real-time release, and ultimately global manufacturing equity. At its core, the company replaces slow, manual, PhD dependent QC and analytical CRO models with automated, FDA aligned digital infrastructure, turning quality control from a bottleneck into a real time, intelligence driven capability.

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 4,500 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US.

For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.com

Media contact:

Guenaelle Holloway, Head of marketing and communications
Guenaelle.Holloway@recipharm.com
+44 7730 303 708